HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials

Autor: Swerdlow, Daniel I, Preiss, David, Kuchenbaecker, Karoline B, Holmes, Michael V, Engmann, Jorgen E L, Shah, Tina, Sofat, Reecha, Stender, Stefan, Johnson, Paul C D, Scott, Robert A, Leusink, Maarten, Verweij, Niek, Sharp, Stephen J, Guo, Yiran, Giambartolomei, Claudia, Chung, Christina, Peasey, Anne, Amuzu, Antoinette, Li, KaWah, Palmen, Jutta, Howard, Philip, Cooper, Jackie A, Drenos, Fotios, Li, Yun R, Lowe, Gordon, Gallacher, John, Stewart, Marlene C W, Tzoulaki, Ioanna, Buxbaum, Sarah G, van der A, Daphne L, Forouhi, Nita G, Onland-Moret, N Charlotte, van der Schouw, Yvonne T, Schnabel, Renate B, Hubacek, Jaroslav A, Kubinova, Ruzena, Baceviciene, Migle, Tamosiunas, Abdonas, Pajak, Andrzej, Topor-Madry, Romanvan, Stepaniak, Urszula, Malyutina, Sofia, Baldassarre, Damiano, Sennblad, Bengt, Tremoli, Elena, de Faire, Ulf, Veglia, Fabrizio, Ford, Ian, Jukema, J Wouter, Westendorp, Rudi G J, de Borst, Gert Jan, de Jong, Pim A, Algra, Ale, Spiering, Wilko, der Zee, Anke H Maitland-van, Klungel, Olaf H, de Boer, Anthonius, Doevendans, Pieter A, Eaton, Charles B, Robinson, Jennifer G, Duggan, David, Kjekshus, John, Downs, John R, Gotto, Antonio M, Keech, Anthony C, Marchioli, Roberto, Tognoni, Gianni, Sever, Peter S, Poulter, Neil R, Waters, David D, Pedersen, Terje R, Amarenco, Pierre, Nakamura, Haruo, McMurray, John J V, Lewsey, James D, Chasman, Daniel I, Ridker, Paul M, Maggioni, Aldo P, Tavazzi, Luigi, Ray, Kausik K, Seshasai, Sreenivasa Rao Kondapally, Manson, JoAnn E, Price, Jackie F, Whincup, Peter H, Morris, Richard W, Lawlor, Debbie A, Smith, George Davey, Ben-Shlomo, Yoav, Schreiner, Pamela J, Fornage, Myriam, Siscovick, David S, Cushman, Mary, Kumari, Meena, Wareham, Nick J, Verschuren, W M Monique, Redline, Susan, Patel, Sanjay R, Whittaker, John C, Hamsten, Anders, Delaney, Joseph A, Dale, Caroline, Gaunt, Tom R, Wong, Andrew, Kuh, Diana, Hardy, Rebecca, Kathiresan, Sekar, Castillo, Berta A, van der Harst, Pim, Brunner, Eric J, Tybjaerg-Hansen, Anne, Marmot, Michael G, Krauss, Ronald M, Tsai, Michael, Coresh, Josef, Hoogeveen, Ronald C, Psaty, Bruce M, Lange, Leslie A, Hakonarson, Hakon, Dudbridge, Frank, Humphries, Steve E, Talmud, Philippa J, Kivimäki, Mika, Timpson, Nicholas J, Langenberg, Claudia, Asselbergs, Folkert W, Voevoda, Mikhail, Bobak, Martin, Pikhart, Hynek, Wilson, James G, Reiner, Alex P, Keating, Brendan J, Hingorani, Aroon D, Sattar, Naveed

Publikováno v: In The Lancet 24-30 January 2015 385(9965):351-361

Accrual and drop out in a primary prevention randomised controlled trial: qualitative study.

Autor: Eborall, Helen C.¹ hce3@le.ac.uk, Stewart, Marlene C. W.², Cunningham-Burley, Sarah³, Price, Jackie F.², Fowkes, F. Gerry R.²

Publikováno v: Trials. 2011, Vol. 12 Issue 1, p1-8. 8p.

HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials

Autor: Swerdlow, Daniel I, Preiss, David, Kuchenbaecker, Karoline B, Holmes, Michael V, Engmann, Jorgen E L, Shah, Tina, Sofat, Reecha, Stender, Stefan, Johnson, Paul C D, Scott, Robert A, Leusink, Maarten, Verweij, Niek, Sharp, Stephen J, Guo, Yiran, Giambartolomei, Claudia, Chung, Christina, Peasey, Anne, Amuzu, Antoinette, Li, KaWah, Palmen, Jutta, Howard, Philip, Cooper, Jackie A, Drenos, Fotios, Li, Yun R, Lowe, Gordon, Gallacher, John, Stewart, Marlene C W, Tzoulaki, Ioanna, Buxbaum, Sarah G, van der A, Daphne L, Forouhi, Nita G, Onland-Moret, N Charlotte, van der Schouw, Yvonne T, Schnabel, Renate B, Hubacek, Jaroslav A, Kubinova, Ruzena, Baceviciene, Migle, Tamosiunas, Abdonas, Pajak, Andrzej, Topor-Madry, Romanvan, Stepaniak, Urszula, Malyutina, Sofia, Baldassarre, Damiano, Sennblad, Bengt, Tremoli, Elena, de Faire, Ulf, der Zee, Anke H Maitland-van, Klungel, Olaf H, de Boer, Anthonius, Dale, Caroline, DIAGRAM Consortium, MAGIC Consortium, InterAct Consortium

BACKGROUND: Statins increase the risk of new-onset type 2 diabetes mellitus. We aimed to assess whether this increase in risk is a consequence of inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), the intended drug target. METHODS: We us

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______101::91f8eca36d69764a082b5ec00d6b7dd3
https://dspace.library.uu.nl/handle/1874/303715

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.